Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2001

View Archived Issues

Enrollment completed for phase I/II StreptAvax trial

ALT-711 may be effective in improving cardiovascular remodeling in hypertension

Phase I trial begins for novel site-specific oral therapy for GI disorders

Antiinflammatory C5a receptor blocker enters clinical testing

Imidazole antifungal agent NND-502 highlighted at Japanese scientific meeting

Chimeric gp41 molecule inhibits HIV fusion at nanomolar concentrations

HEV vaccine advances to phase II trials

October meeting date set for vote on Microcide/Althexis merger

NIH funds further development of experimental stroke therapy; PNAS article supports new strategy

Intratracheal AWD-12-281 significantly reduces LPS-induced BALF neutrophilia in pigs

BMS-284640 is more potent and more selective for NHE-1 than cariporide

INS-316 enhances sputum quality for lung cancer diagnosis

Lead compound targeting fungal N-myristoyltransferase identified by Nippon Roche

NeoTherapeutics files IND to begin clinical studies with drug targeting severe dementia

Atrix submits NDA for Leuprogel Three-Month Depot for prostate cancer

Full enrollment reached in Vasogen psoriasis trial

Pharmexa cleared to begin phase I/II breast cancer trial in the U.K.

GenStar's hemophilia A gene therapy trial resumes after previous delay

ERS highlights: NIK-616 may have advantages for Rx of asthma and COPD

New PDE4 inhibitor CI-1044 may be useful in COPD, according to ERS presentation

New dopamine D4 ligands from Lundbeck and potential therapeutic uses

1-Methylcarbapenems with excellent antibacterial activity, safety and pharmacokinetics

Potent and selective MCP-1 antagonists identified by Daiichi

Daiichi's new squalene synthase and cholesterol biosynthesis inhibitors patented

Eisai presents new sodium channel inhibitors with antiarrhythmic activity

New series from Teijin inhibits human chymase, particularly mast cell enzyme

Selective Gardos channel inhibitors useful in sickle cell disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...